Acetyl Hexapeptide-8 modulates muscular contractions by competitively inhibiting the synaptic protein complex:

• SNARE Complex Competition: With a molecular weight of 825.9 g/mol, the peptide mimics the N-terminal of SNAP-25, blocking the fusion pore formation required for acetylcholine release.
• The 500-Dalton Barrier: To achieve dermal impact, R&D labs must utilize penetration enhancers (e.g., liposomes) to fluidize the stratum corneum, as passive diffusion for an 800+ Dalton peptide is biophysically impossible.

• HPLC Purity ≥ 99.0%: Elimination of "deletion sequences" to prevent immunogenic reactions and inflammatory erythema in sensitive formulations.
• Residual Acetic Acid ≤ 8.0%: Prevents the ionic collapse of Carbomer networks, ensuring viscosity stability on the factory floor.
• Processing Mandate: Cold-process only (Temp < 35°C). Maintain formulation pH between 5.5 and 6.0 for optimal peptide bond integrity.

As a concentrated API powder, it has not been neutralized, buffered, or stabilized for direct contact with human tissue. Direct application may cause severe irritation, pH-related burns, or systemic toxicity due to high concentration. It is a precursor, not a retail product.

Yes, provided the formulation is prepared in an aseptic environment. Our microbial limit of ≤ 100 cfu/g is specifically controlled to accommodate research where the skin barrier is bypassed, reducing the risk of inflammatory infections.

Xi'an Tihealth provides a full technical dossier, including the COA, MSDS, and specific Batch Manufacturing Records (BMR) to support compliance with local drug regulatory frameworks (FDA/EMA/NMPA).